# AI-Powered Clinical Data Integrity Auditor

## Description
AI-Powered Clinical Data Integrity Auditor is an enterprise, audit-only product for clinical informatics and data governance teams. It evaluates FHIR patient records for cross-resource consistency issues before they become operational or risk-management problems. It never diagnoses or alters clinical intent; deterministic rules establish findings, and AI provides evidence-centered explanation and confidence context.

## Problems & Solutions

### Problem 1: Cross-resource clinical contradictions undermine trust
**Who is affected:** Clinical informatics teams, data governance, auditors, and downstream care/operations users
**Impact:** Conflicting statuses across FHIR resources create unsafe ambiguity, rework, and low trust in chart data (for example, inactive medication still referenced as active in a care plan)
**How this product solves it:** Deterministic audit rules establish contradictions across related FHIR resources; AI then explains the issue, presents supporting evidence, assigns severity, and suggests resolution paths.

### Problem 2: Stale and temporally invalid records persist undetected
**Who is affected:** Quality teams, operations, compliance stakeholders, and any workflow depending on longitudinal data integrity
**Impact:** Outdated states, impossible event sequences, and unresolved data drift propagate into audits, reporting, and operational decisions
**How this product solves it:** Deterministic timeline and state rules detect stale conditions and temporal violations; AI provides evidence-backed rationale and prioritization for triage.

### Problem 3: Missing or unsupported expected relationships hide integrity gaps
**Who is affected:** Data stewards, interoperability teams, reviewers, and governance/compliance owners
**Impact:** Expected links defined by audit policy are absent or unsupported, reducing interpretability and increasing reconciliation effort
**How this product solves it:** Rule-defined relationship checks identify missing or unsupported expected links; AI explains why the gap matters and recommends non-diagnostic corrective actions while preserving clinical intent.

### Problem 4: False confidence from locally valid but globally inconsistent data
**Who is affected:** Clinicians, quality reviewers, operational leaders, and compliance teams relying on chart-level integrity
**Impact:** Individual FHIR resources may appear valid in isolation, creating a misleading sense of reliability while cross-resource contradictions remain hidden
**How this product solves it:** The auditor performs cross-resource consistency checks where deterministic rules establish contradiction conditions and AI supplies explanation, evidence traceability, and risk-based prioritization.

## Key Features
- Cross-resource contradiction auditing across FHIR patient records to detect conflicts that are invisible when reviewing resources in isolation.
- Rule-defined integrity checks for stale states, timeline violations, and missing or unsupported relationships expected by explicit audit policy.
- Deterministic-first adjudication: rules establish whether a contradiction exists; AI contributes explanation, evidence synthesis, and contextual reasoning only after detection.
- Evidence-backed issue packets for each finding: conflicting records, severity, explanation, recommended resolution, and source traceability for review.
- Risk-based prioritization and triage support so teams can address highest-risk and highest-operational-impact integrity issues first.
- Audit transparency for every finding: rule ID, records evaluated, evidence, AI rationale and confidence context, timestamp, and audit outcome.
- Safety-bound auditing mode that enforces non-diagnostic behavior and preserves clinical intent while improving data quality and auditability.
- Enterprise governance support for data quality, operational reliability, risk management, and compliance reporting.

## Success Criteria
- Detect at least 95% of known contradiction scenarios in the MVP/pilot rule pack on benchmark datasets.
- Populate at least 90% of findings with complete audit transparency fields: rule ID, records evaluated, evidence, AI rationale and confidence context, timestamp, and audit outcome.
- Achieve at least 85% human-auditor acceptance that findings are correctly prioritized and actionable during MVP/pilot.
- Reduce median time-to-triage for high-severity integrity findings by at least 40% versus current manual review baseline in pilot operations.
- Keep high-severity false-positive rate below 10% during MVP/pilot.
- Preserve safety boundary in 100% of sampled findings: no diagnostic claims, no treatment recommendations, and no alteration of clinical intent.
- Reach at least 80% positive feedback from pilot users in data governance/clinical informatics on increased trust in cross-resource consistency.
- Reproduce 100% of sampled findings from logged artifacts (rule, inputs, evidence, rationale, and outcome) without re-running the full pipeline.

## Scope
**In:** Auditing FHIR patient record consistency across Conditions, Medications, Procedures, Encounters, Observations, and CarePlans; deterministic rule execution for contradictions, stale states, timeline violations, and missing or unsupported relationships expected by defined audit rules; AI-assisted explanation and evidence synthesis for already-detected findings with rationale and confidence context; severity scoring and risk-based prioritization; audit transparency payload per finding; data-governance-oriented resolution suggestions; batch-oriented auditing workflows; reproducible logs and evidence traceability; MVP/pilot target measurement.
**Out:** Any diagnostic conclusion, treatment recommendation, or alteration of clinical intent; replacing clinician judgment or acting as bedside decision-support; real-time autonomous clinical intervention; auto-remediation that mutates source records without governance approval; broad interoperability platform replacement; claims of universal clinical truth beyond explicit, rule-defined audit expectations.

## Assumptions & Open Questions

| # | Item | Risk / Impact | Owner |
|---|------|---------------|-------|
| 1 | MVP/pilot targets (95/90/85/40/10/80) are treated as pilot goals, not production baselines. | Premature baseline claims can damage rollout credibility and governance trust. | Product + Clinical Informatics |
| 2 | Deterministic engine is authoritative for contradiction detection; AI provides rationale and confidence context only. | If this boundary blurs, safety/compliance risk rises and audit defensibility weakens. | Architecture + Safety/Compliance |
| 3 | Initial scope uses defined FHIR resources with stable profile mappings. | Incomplete mappings can inflate false positives and reduce reviewer trust. | Interoperability Lead |
| 4 | Missing/unsupported relationships are evaluated only against explicit audit rules, not universal clinical truth. | Without explicit rule catalogs, findings may be misread as clinical judgment. | Rule Governance Board |
| 5 | Required transparency fields can be captured end-to-end for each finding. | Missing fields undermine reproducibility and compliance review. | Platform Engineering + Audit/Compliance |
| 6 | Mixed ownership resolution workflow can be operationalized with clear handoffs. | Ambiguous ownership leads to unresolved findings and low operational value. | Operations + Data Governance |
| 7 | Benchmark datasets with labeled contradiction scenarios are available or can be created. | Without benchmark truth sets, MVP target validation is weak. | Data Science + QA |
| 8 | High-severity triage SLAs and escalation policies can be defined before pilot. | If SLAs are undefined, high-risk findings may not be actioned in time, reducing operational/risk-management value. | Clinical Operations + Risk Management |
| 9 | Accepted false-positive tolerance can be agreed by stakeholders before pilot. | Misaligned tolerance causes alert fatigue or under-detection risk. | Clinical Informatics + Product |
| 10 | Regulatory/compliance stakeholders accept audit-only positioning (no diagnosis, no clinical intent alteration). | If stakeholders expect CDS behavior, product fit and approvals may stall. | Compliance + Product Leadership |
